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Available online 20 August 2013AbstractBackground/ introduction: The employed antibiotic could be ineffective against acute health effect causing multidrug resistant enteropathogenic
bacteria. Thus, phytodrugs could be used for its control.
Aims/purpose: Leaf and bark extracts of Terminalia alata, an ethnomedicinal plant used for ailments of the human gastrointestinal tract, were
assessed for antibacterial efficacy in vitro, against eight enteropathogenic, extended spectrum b-lactamase enzyme producing multidrug resistant
bacteria.
Materials and methods: Pathogenic bacteria were typified with serial biochemical steps. The double-disc diffusionesynergy test was used for the
determination of extended spectrum b-lactamase producers. Sixteen antibiotics were used for determining antibiograms of eight isolated
bacteria, using the disc-diffusion method. Antibacterial efficacies, of plant-extracts obtained using eight solvents, were monitored by the agar-
well diffusion method. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of plant-extracts using
solvents, methanol, ethanol, and acetone were determined by the micro-broth dilution method. Seven qualitative phytochemical tests were done
with plant extracts.
Results: Of 16 antibiotics, resistant patterns were recorded with 14 antibiotics for Enterobacter aerogenes strains, 13 for Escherichia coli, 14 for
Klebsiella sp., seven for Salmonella paratyphi, 15 for Salmonella typhi, 14 for two species of Shigella, and four for Vibrio cholerae. It was found
that plant extracts using petroleum ether and n-hexane had the least antibacterial activity. Leaf and bark extracts using methanol, ethanol, and
acetone registered the highest antibacterial activities with all these bacteria. The methanolic bark extract recorded MIC values, of 1.56 mg/mL
against E. coli, Klebsiella sp., S. paratyphi, Shigella dysenteriae, and Shigella sonnei; 3.13 mg/mL against E. aerogenes and S. typhi; and
12.5 mg/mL against V. cholerae. The MBC values of the methanolic bark extract were: 12.5 mg/mL against E. coli, Klebsiella sp., S. dysen-
teriae, and S. sonnei; 25 mg/mL against E. aerogenes, S. typhi, and S. paratyphi; and 50 mg/mL against V. cholerae. Phytochemical analyses of
methanolic leaf and bark extracts of T. alata confirmed the presence of alkaloids, terpenoids, reducing sugars, tannins, and flavonoids.
Conclusion: The antibacterial efficacy of methanolic crude extracts revealed that leaves and bark of T. alata could serve as complementary/
supplementary medicines to control multidrug resistant enteropathogenic bacteria.
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Keywords: Antibacterial activity; Enteropathogenic bacteria; Minimum bactericidal concentration; Minimum inhibitory concentration; Phytochemical analysis;
Terminalia alata* Corresponding author. Central Research Laboratory, IMS & Sum Hospital, Siksha ‘O’ Anusandhan University, Kalinga Nagar, Bhubaneswar 751003, Odish
India.
E-mail address: rnpadhy54@yahoo.com (R.N. Padhy).
2211-5587/$ - see front matter Copyright  2013, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
http://dx.doi.org/10.1016/j.jacme.2013.06.002a,
94 S. Rath, R.N. Padhy / Journal of Acute Medicine 3 (2013) 93e1021. Introduction
Terminalia alata Heyne ex. Roth (Indian laurel, locally
Sahaja, family Combretaceae) is a deciduous tree with gray or
black, deeply cracked rough bark, native to India, and found in
Myanmar, Indo-China, and Thailand. The tree normally grows
to a height of 30e35 m (Fig. 1). Traditionally, T. alata bark
has been widely used in Indian ethnomedicine and Ayurveda
for a variety of purposes. The brew of bark is diuretic, styptic,
and cardiotonic; it is used against hemorrhage, ulcers, frac-
tures, bronchitis, diarrhea, fever, boils, pruritus, and diseases
of the head; also its gum is used as a purgative.1 About 3e4
teaspoonfuls of fresh bark juice (about 50 g bark crushed in 10
teaspoonfuls of water and filtered) are taken 3 times a day to
cure diarrhea and dysentery.2,3
Traditional medicines with plants and other natural products
are often the major accessible and affordable means of health-
care needs for marginalized people in the developing countries
of Asia, Africa, and Latin America, because of efficacy and low
cost. Nonedible plants, used in folk medicines traditionally
worldwide, are rich sources of natural chemicals of secondary
metabolism, and those are, or could be, formulated for modern
medicines for several health conditions.4 More than 80% of the
world’s population, often consisting of the elite, relies on plant-
based products to meet their healthcare needs; 25e45% of
prescriptions today of the modern medicinal system contain
plant-derived molecules as basic sources.5 Prior to the advent of
synthetic drugs and antibiotics, phytodrugs in crude extracts
have been used for healthcare needs ranging from food sup-
plements and antioxidants to pharmaceutically manipulated
intermediates for the synthesis of dovetailed drugs for several
diseases, giving way to the system of complementary and
alternative medicine (CAM). Explicit information, originally
obtained from folklore information across diverse cultures with
plants, is being embarked scientifically as CAM, because crude
extracts of several plants are continually scaled up, for indi-
vidual use or as coalesced concoctions against a myriad of ail-
ments, worldwide.4,6e8 Many phytodrugs, such as morphine,
quinine, and digoxindiconic pure phytochemicals are effectiveFig. 1. Terminalia alata.for specific health problems. A survey by the World Health
Organization (WHO) found that the following proportions of
populations use CAM for healthcare needs yields the following:
Chile 71%, Columbia 40%, African nations 80%, China 40%,
India 45%, among developing countries; and, Australia 48%,
Canada 70%, USA 42%, Belgium 38%, and France 75% for
developed countries.9 Furthermore, annual expenditure on CAM
was United States Dollar (USD) 500 million in Malaysia,
annually compared to USD 300 million for allopathic drugs. In
the USA, Australia, UK, and Canada, the annual use of CAM
was estimated at USD 300 million, USD 80 million, USD 2300
million, and USD 2400 million, respectively.9 The value of
plant-based prescribed drugs in 1990 was estimated at USD 15.5
billion, which has been on the rise since then to USD 35 billion,
during the past decade.10,11 Not surprisingly, about 42% of the
25 top-selling phytodrugs marketed worldwide are either
directly obtained from natural sources or their products.12 The
Indian herbal market is growing fast and should have attained
the level of USD 265 billon per annum by 2012, as conjectured
from available trends. In particular, the herbal industry potential
has revealed that recently the Indian herbal market size was
estimated at USD 130 billion, and more than USD 65 billion of
herbal raw materials and medicines were exported by India by
2010.11 This indicated that herbal trade markets and the use of
herbal products must be developing in each country, and are not
being systematically recorded in databases. Indeed, herbal
products are widely recommended today for health boosting and
as preventives byWHO,13 and in future would be recommended
for more specific needs as CAM, if those could be scaled as
remedial measures, without any dyslogistic prejudice. Obvi-
ously, host-toxicity testing of nonedible plant-products remains
an essential corollary in CAM for scientific validation. In India,
people from the marginalized sectiondslum-dwellers and
aboriginesdas well as the sophisticated, elite population
habitually use concoctions of crude phytodrugs such as the
Ayurvedic, Unani, and Siddha systems.10,14 Similar medicinal
systems are also in the cultural practices of people of other
countries; eventually, phytotoxicity against hosts is frequently
recorded.15 The developed world also has a renewal of interest
towards the use of herbal medicines for health boosting or health
conditioning and for treating/preventing several common or rare
ailments, despite the ready availability of modern medicine.9 As
pharmacology has been acknowledging medicinal plants as the
potential sources of bioactive compounds, crude phytoextracts
need be considered logistically.
Intractable bacterial infections cause mortality as terminal
diseases, and millions suffer chronically from several long-
standing infections. On analysis, it is often found that some
drug-resistant bacterium is the causative organism of
morbidity. Pathogenic bacteria gain multidrug resistant (MDR)
traits due to their simple genomes, and consortia of bacteria in
nature help their evolution by exchanges of their genetic ma-
terials.10 Consequently, MDR bacteria emerge, causing diverse
morbidity and disproportionate mortality. Obviously, several
clinical and social factors contribute to the problem of the
emergence of MDR pathogens, as detailed elsewhere.16
Furthermore, a WHO survey identified a rate of nosocomial
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pitals of 14 countries as early as in 1983.17 However, the
infection rate was different from one study to another, ranging
from 1% in the USA to more than 30% in less-developed
countries, where hospital-care facilities were limited.18 About,
45% of total pus specimens from patients with nosocomial
surgical site infections were positive for the growth of Escher-
ichia coli (26.47%), Pseudomonas aeruginosa (17.65%), Aci-
netobacter sp. (11.77%), and Staphylococcus aureus
(8.82%).19,20 There are five genera of pathogenic bacteria that
are pandrug resistant, i.e., some strains of these bacteria are
resistant to almost all antibiotics: Mycobacterium tubercu-
losis,21 S. aureus,22 and three Gram-negative (GN) bacteria:
Acinetobacter baumannii, P. aeruginosa andKlebsiella sp.23 An
antibiogram of 23 antibiotics tested for E. coli (the most com-
mon enteric and urinary tract infection causing pathogen)
revealed the progressive increase of drug-resistance against each
antibiotic, with the maximum resistant values recorded in
nosocomial isolates from this hospital being: gentamicin, 92%;
oxacillin, 92%; ceftriaxone, 85%; and norfloxacin, 97%.24 The
outbreak of accredited MDR strains of pathogens should affect
economic and public health sectors, leading to an urgent
implementation of some avant-garde drugs as antimicrobials.
Plants provide an acceptable source of drugs.
From this perspective, certain medicinal plants could serve
as sources of nonmicrobial antimicrobials for the control of
infectious diseases from several MDR bacteria, as seen with
crude phytoextracts of several lesser-known plants.25e28
Although the chemoprophylaxis and Streptomyces sources of
antibiotics are not exhausted, many plants have a history of
ethnic uses for the control of infectious ailments. Because no
microbe, no matter how genetically well equipped, is likely to
over-ride crude plant-extracts for the plethora of inherent
phytochemicals as nonmicrobial antimicrobials,29,30 taking
recourse to plants for the control of MDR pathogens would be
a prudent alternative. Their efficacies need to be evaluated
with mammalian systems. As each plant has a rich ethnobo-
tanical literature behind it, i.e., being age-tested, host toxicity
testing with nonpoisonous effective plants would become
logistically redundant, when the urgency of the control of
MDR bacteria is considered pruriently. Plants, being rich in
secondary metabolites such as, alkaloids, flavonoids, and
tannins that have antimicrobial properties as indicated else-
where,28 with holistic control capacity. The plant T. alata,
from which edible brew is prepared from bark could be suit-
able for the control of MDR enteropathogens, as this plant has
been described in folklore literature as having control capacity
on enteric diseases. For instance, in a screening attempt of 25
plants against 10 enteric bacteria, T. Alata was found to have
good in vitro antibacterial activity.3 Continuing in the same
line of work, T. alata was chosen for a detailed analysis of its
efficacy, after extraction with eight polar to nonpolar organic
solvents. From time immemorial, this plant has been serving
holistically as medicine, but there is no record of its micro-
biological validation in controlling bacteria. This paper reports
data of in vitro efficacies of multiple solvent extracts of leaves
and bark of T. alata against eight continually evolvingclinically isolated enteric pathogens, coupled with the deter-
mination of lethal concentrations of active crude extracts, as
well as antibiograms with 16 antibiotics from six groups.
Furthermore, qualitative phytochemical analyses were done
for possibilities of linking the antibacterial activity of the plant
to its constituents. It is anticipated that this study should help
in distinguishing the plant for further use in harnessing anti-
microbials for these MDR enteropathogens.
2. Materials and methods2.1. Preparation of plant extractsFor hot extraction (extraction with a temperature below the
boiling point of the organic solvent in use), a 40 g sample of
powdered plant material (both leaves and bark, separately) of T.
alata was dissolved in approximately 400 mL of organic sol-
vent in a Soxhlet apparatus (Borosil, Kolkata, India). According
to the successive extraction procedure, eight nonpolar to polar
solvents (petroleum ether, ethyl acetate, chloroform, n-hexane,
acetone, methanol, ethanol, and water) were used; extractions
were carried out at 40e60C, depending upon the boiling point
of the organic solvent in use. After approximately 40 cycles or
siphons with petroleum ether, the liquid extract was collected at
the bottom flask and was dried using the rotary evaporator until
a semisolid mass was obtained, which was stored in 10%
dimethyl sulfoxide (DMSO) solution, at 4C for use. The
leftover plant material in the Soxhlet apparatus was further
oven dried at 40C and was reused for another extract using the
next solvent in the succession list, cited above.282.2. Isolation and biochemical identification of bacterial
isolatesStrains of eight enteropathogenic bacteria (Enterobacter
aerogenes, Escherichia coli, Klebsiella sp., Salmonella para-
typhi, Salmonella typhi, Shigella dysenteriae, Shigella sonnei,
and Vibrio cholera) were isolated from clinical samples of pa-
tients at IMS & Sum Hospital. Maintenance of isolated bacteria
on suitable media and biochemical identifications of bacterial
strains along with corresponding strains from Microbial Type
Culture Collections (MTCC), viz.,E. aerogenesMTCC2990,E.
coli 443, Klebsiella sp. 4031, S. paratyphi 3220, S. typhi 733, S.
sonnei 2957, and V. cholera MTCC 3905 were done, as
described previously.3 Colony characters and biochemical tests
ascertained the identification of the bacterial strains.2.3. Antibiotic susceptibility testAll bacterial strains including MTCC standard strains
(Table 1) were subjected to antibiotic sensitivity tests by the
Kirby-Bauer/disc-diffusion method, using a 4 mm thick
MuellereHinton (MH) agar (Hi Media Laboratories Private
Limited, Mumbai, India) medium, in duplicates.26,31 An aliquot
of 0.1 mL of 0.5 McFarland equivalents, approximately, from
an exponentially growing culture was spread on agar for the
development of lawn of bacteria at 37C in a biochemical
Table 1
Antibiotic susceptibility of enteropathogenic bacteria.
Bacteria Susceptibility to prescribed antibiotic groups
Amino-glycosides b-lactams Cephalosporins Fluoroquinolones Sulfonamide Stand-alones
Ac Ge Am Ak Pt Ce Cf Ci Gf Na No Of Cot Ch Nf Te
Enterobacter aerogenes R R R R R R R S R R R R R S R I
Escherichia coli R R R R R R R S R R R R S S R R
Klebsiella sp. R S R R R R R R R R R R R S R R
Salmonella paratyphi S S R R S R R S R S S S R S I S
Salmonella typhi R R R R R R R I R R R R R S R R
Shigella dysenteriae R I R R R R R S R R R R R S R R
Shigella sonnei R R R R R R R S R R R R R S R I
Vibrio cholerae R R S S S R S S S S S S R S S S
I ¼ moderately sensitive; R ¼ resistant; S ¼ sensitive. Antibiotics (mg/disc): Ac ¼ amikacin 30; Ak ¼ amoxyclav 30; Am ¼ ampicillin 10; Ce ¼ ceftriaxone 30;
Cf ¼ cefpodoxime 10; Ch ¼ chloramphenicol 30; Ci ¼ ciprofloxacin 5; Cot ¼ co-trimoxazole 25; Ge ¼ gentamicin 10; Gf ¼ gatifloxacin 5; Na ¼ nalidixic acid
30; Nf ¼ nitrofurantoin 300; No ¼ norfloxacin 10; Of ¼ ofloxacin 5; Pt ¼ piperacillin/tazobactam 100/10; Te ¼ tetracycline 30.
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Laboratory Instruments, Kolkata, India). On the lawn-agar of
each plate, eight high potency antibiotic discs (HiMedia) of 16
prescribed antibiotics were placed, separately at equal distances
from one another. Plates were incubated for 18 hours at 37 C
and were examined for the size of zones of inhibition around
each disc, following the standard antibiotic susceptibility test
chart of the Clinical Laboratory Standard Institute (CLSI)
guidelines.32 Experiments were done three times and data of the
third set of experiments are presented (Table 1).2.4. Detection of extended spectrum b-lactamase
producersThe double-disc diffusionesynergy test was used for the
determination of extended spectrum b-lactamase (ESBL) pro-
ducers in eight GN bacteria. In this test, synergy was determined
between a disc of augmentin (a combination of amoxicillin 20
and clavulanic acid 10 mg) and two discs of third-generation
cephalosporin antibiotics (ceftazidime 30 mg and cefotaxime
30 mg),all placed at equidistant positions 30 mm apart on the
lawn culture of a test bacterium on aMH agar plate, in duplicate.
The test bacterium was considered as ESBL producing if the
inhibition-zone size around both/one test antibiotic discs
increased towards the augmentin disc (Fig. 2), because the
clavulanic acid present in the augmentin disc is inactivated by
the ESBL enzyme, produced by the test bacterium.16,282.5. Agar-well diffusion method for antibacterial activity
testFig. 2. Double-disc synergy test for ESBL detection.Antibacterial activities of the eight different solvent ex-
tracts of the plant were done by the agar-well diffusion
method.26,28 One strain from each bacterial species having
resistance to maximum numbers of antibiotics was used, for
monitoring antibacterial activities of plant extracts. Bacterial
lawns were prepared with 6 mm thick agar that was fully
punched and 6e8 wells were prepared, when a lawn was 30
minutes old, and each well was based by 50 mL molten MH
agar, in duplicates. Wells were filled with 100 mL aliquots of30 mg/mL solvent-extracts of T. alata, diluted from the orig-
inal stock of plant extracts of individual organic solvents with
the aqueous extract, by 10% DMSO solution. Plates were
incubated at 37C for 18e24 hours. Antibacterial activities
were evaluated by measuring the diameter values of zones of
inhibition. Experiments with each solvent extract were con-
ducted three times and data of the third repeated experiment
are presented (Table 2). An aliquot of 100 mL of chloram-
phenicol 30 mg/mL with an average diameter of zone of in-
hibition of 21 mm and 10% DMSO solution were reference
controls28; 10% DMSO solution had no antibacterial activity.2.6. Determination of minimum inhibitory and
bactericidal concentrationsMinimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) of three active plant-
extracts, prepared with methanol, ethanol, and acetone were
determined, by suitable dilutions from original stock solutions
Table 2
Antimicrobial assay, as zone of inhibition by the agar-well diffusion method of leaf (and bark) extracts with different hot solvents of Terminalia alata against MDR
enteropathogenic bacteria (mm).
MDR bacteria Petroleum ether Ethyl acetate Chloroform n-Hexane Acetone Ethanol Methanol Water Chl
Enterobacter aerogenes 6 (8) 12 (16) 14 (16) 13 (16) 20 (21) 21 (23) 22 (25) 15 (17) 21
Escherichia coli e (7) 11 (17) 16 (18) 15 (17) 18 (20) 21 (22) 21 (26) 15 (21) 20
Klebsiella sp. e 10 (14) 15 (17) 14 (17) 19 (21) 19 (23) 24 (26) 16 (20) 21
Salmonella paratyphi e 13 (15) 13 (16) 14 (18) 20 (20) 20 (21) 21 (23) 14 (17) 20
Salmonella typhi e 13 (16) 14 (16) 13 (15) 18 (19) 21 (24) 23 (25) 14 (18) 22
Shigella dysenteriae e (4) 15 (16) 15 (17) 15 (18) 18 (21) 20 (24) 23 (26) 15 (19) 21
Shigella sonnei e (6) 13 (14) 13 (16) 14 (17) 19 (20) 21 (23) 21 (25) 13 (17) 20
Vibrio cholerae e 7 (11) 8 (11) 12 (15) 14 (16) 15 (17) 16 (19) 11 (16) 21
Numbers in parentheses represent those for bark extract.
Chl ¼ chloramphenicol 30 mg/mL.
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1.562 mg/mL, 3.125 mg/mL, 6.25 mg/mL, 12.5 mg/mL,
25 mg/mL, 50 mg/mL, and 100 mg /mL in aliquots of 10%
DMSO solution. Separate experiments were conducted for
each solvent extract. An aliquot of 80 mL of each dilution of a
solvent-extract was released to a well on a 96-well (12  8)
microtiter plate, along with 100 mL MH broth (HiMedia),
20 mL bacterial inoculum (109 colony forming units/mL) and
5 mL of 0.5% 2,3,5-triphenyl tetrazolium chloride. After
pouring all the above materials to a well, the microtiter plate
was incubated at 37C for 18 hours. The development of a
pink coloration due to triphenyl tetrazolium chloride in a well
indicated bacterial growth and the absence of the coloration
was taken as the growth inhibition. The first well of the mi-
crotiter plate was the control, without any plant extract. The
MIC value was noted as the concentration in the well where
pink color was not manifested. Bacteria from each well of the
microtiter plate were subcultured onto nutrient agar; the level
of dilution, where no bacterial growth on the nutrient agar was
observed was noted as the MBC value.28 Results of the second
repeated experiment are presented (Tables 3 and 4).2.7. Phytochemical analyses1. Test for reducing sugars. The presence of free reducing
sugars was ascertained by Fehling’s test.
2. Test for saponins. A 0.5 g samples of an extract was dis-
solved in 10 mL of distilled water in a test-tube, which wasTable 3
Minimum inhibitory concentration (MIC) and minimum bactericidal concen-
tration (MBC) values of three bioactive leaf extracts of Terminalia alata
against multidrug-resistant enteropathogenic bacteria (mg/mL).
Bacteria Methanol Ethanol Acetone
MIC MBC MIC MBC MIC MBC
Enterobacter aerogenes 3.13 12.5 3.125 6.25 3.125 12.5
Escherichia coli 3.13 12.5 3.125 12.5 6.25 25.0
Klebsiella sp. 1.56 12.5 6.25 25.0 3.125 25.0
Salmonella paratyphi 6.25 25.0 3.125 12.5 3.125 25.0
Salmonella typhi 3.13 25.0 3.125 12.5 6.25 50.0
Shigella dysenteriae 1.56 12.5 6.25 25.5 6.25 25.0
Shigella sonnei 3.13 12.5 3.125 12.5 6.25 25.0
Vibrio cholerae 12.5 50.0 12.50 50.0 12.50 50.0shaken vigorously for 30 seconds and subsequently was
allowed to stand for 45 minutes. The appearance of frothing
on warming the sample indicated the presence of saponins.
3. Test for flavonoids. To a portion of the dissolved extract, a
few drops of 10% ferric chloride solution were added. A
green or blue coloration indicated the presence of flavonoids.
4. Test for steroids/terpenes. A 0.5 g sample of the concen-
trated mass of the plant-extract from the rotary evaporator
was dissolved in 2 mL of acetic anhydride and the mixture
was cooled at 0e4C, and a few drops of 12 N sulfuric
acid was carefully added. A color change from violet to
blue-green indicated the presence of a steroidal nucleus.
5. Test for tannins. A 0.5 g sample of the extract was dis-
solved in 5 mL of water followed by the addition of a few
drops of 10% ferric chloride solution. A blue-black, green,
or blue-green precipitate indicated the presence of tannins.
6. Test for alkaloids. A 0.5 g sample of plant-extract was
stirred with 5 mL 1% HCl on a steam bath, and the
mixture was filtrated; a few drops of Mayer’s reagent
(1.36 g HgCl2, 5 g KI in 100 mL distilled water) were
added to 1 mL of the filtrate, and to another aliquot of
1 mL of the filtrate, a few drops of Dragendorff’s reagent
[two solutions in 1:1 ratio: Solution A (0.85 g bismuth
nitrate, 10 mL glacial acetic acid, and 40 mL distilled
water); and Solution B (8 g KI in 30 mL distilled water)]
were added. Turbidity or precipitation in tubes due to
either of these reagents indicated the presence of alkaloids
in the extract.Table 4
Minimum inhibitory concentration (MIC) and minimum bactericidal concen-
tration (MBC) values of bioactive bark extracts of Terminalia alata against
multidrug-resistant enteropathogenic bacteria (mg/mL).
Bacteria Methanol Ethanol Acetone
MIC MBC MIC MBC MIC MBC
Enterobacter aerogenes 3.13 25.0 3.13 6.25 3.13 12.5
Escherichia coli 1.56 12.5 3.13 12.5 6.25 25.0
Klebsiella sp. 1.56 12.5 6.25 50.0 3.13 25.0
Salmonella paratyphi 1.56 25.0 3.13 12.5 3.13 25.0
Salmonella typhi 3.13 25.0 1.56 12.5 6.25 25.0
Shigella dysenteriae 1.56 12.5 1.56 12.5 3.13 12.5
Shigella sonnei 1.56 12.5 3.13 12.5 3.13 12.5
Vibrio cholerae 12.5 50.0 12.5 50.0 12.5 50.0
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mixed with 2 mL of glacial acetic acid (1.048 g/mL), one
drop of 1% FeCl3 solution was added and mixed thor-
oughly, and 1 mL of 12 N H2SO4 was added. A brown ring
at the interface indicated the presence of glycosides.26,28
All these tests were repeated for confirmation.
3. Results3.1. Antibacterial workAntibiotic susceptibility tests of the eight GN bacteria were
carried out using 16 antibiotics of six different groups. The
isolated E. aerogenes strain was found to be fully sensitive to
two antibiotics, ciprofloxacin and chloramphenicol, and
moderately sensitive to tetracycline, whereas it was found to
be totally resistant to the remaining 13 antibiotics. Similarly,
the S. paratyphi strain was resistant to six antibiotics (ampi-
cillin, amoxyclav, ceftriaxone, cefpodoxime, gatifloxacin, and
co-trimoxazole) but moderately sensitive to ciprofloxacin and
fully sensitive to the other eight antibiotics. Likewise, anti-
biograms of the other six enteropathogenic GN bacterial
strains were recorded (Table 1); the V. cholerae strain was
resistant to amikacin, gentamicin, ceftriaxone, and co-
trimoxazole only. All isolated GN bacteria were ESBL pro-
ducers, as most isolates were resistant to both cephalosporin
antibiotics (Table 1). Among the tested bacteria S. typhi was
the most resistant bacterium while, V. cholerae was the least
resistant.
Among eight solvent extracts of the plant, the methanolic
leaf and extracts gave the maximum size of inhibition zone
against all bacteria tested. Leaf and bark extracts using pe-
troleum ether registered insignificant antibacterial activities, as
compared to the other seven solvent-extracts against all bac-
teria. In general, each bark extract was recorded exhibiting
better antibacterial properties in comparison to the corre-
sponding leaf extract. Our results showed that methanol was
the best available solvent of extraction for both bark and
leaves followed by ethanol, acetone, water, chloroform, ethyl
acetate, and petroleum ether (Table 2).3.2. MIC and MBC valuesMIC and MBC values of methanol, ethanol, and acetone
extracts from leaf (Table 3) and bark (Table 4) were deter-
mined as these registered the maximum antibacterial activities.Table 5
Phytochemical analysis of Terminalia alata.
Plant part Solvent extracts Alkaloids Glycosides Terpenoids
Leaves Methanol þ þ þ
Ethanol þ þ þ
Acetone þ  þ
Bark Methanol þ þ þ
Ethanol þ þ þ
Acetone þ  þ
þ ¼ present;  ¼ absent.Higher levels of methanolic leaf/bark extracts were required to
control the bacteria in the decreasing order: V. cholerae
followed by S. typhi, E. aerogenes, E. coli, Klebsiella sp,
S. dysenteriae and S. sonnei.3.3. Phytochemical analysesThe presence of alkaloids, glycosides, terpenoids, flavo-
noids, reducing sugars, tannins, and steroids were confirmed
by qualitative phytochemical analysis of the methanolic leaf
extract, but saponins were absent. By contrast, the methanolic
bark extract had all eight phytocompounds. Similarly, the
presence of alkaloids, glycosides, terpenoids, flavonoids, tan-
nins, and saponins was confirmed by phytochemical analysis
of the ethanolic leaf extract, but reducing sugars and steroids
were absent. Thus, all the cited phytocompounds except ste-
roids were present in the ethanolic bark extract. Further, in the
acetone leaf extract, the presence of alkaloids, terpenoids,
flavonoids, tannins reducing sugars, and saponins was
confirmed, but glycosides and steroids were absent. The
presence of alkaloids, terpenoids, reducing sugars, tannins,
and flavonoids was recorded, with the absence of glycosides,
saponins, and steroids in the acetone bark extract (Table 5).
4. Discussion
Antibiograms of eight enteropathogenic bacteria in this
study, with 16 antibiotics of six classes of the day, clearly
indicated that six bacteria, except V. cholerae and S. paratyphi,
were resistant to almost all antibiotics used. Moreover, volumes/
compendia of accumulated literature on the use of crude extracts
and identified phytochemicals described so far, in studies on
antimicrobial efficacy have records on drug-sensitive/standard
strains of bacteria from culture collection centers.10,14,33 This
work has an over-riding importance, as all these bacterial iso-
lates were MDR and isolated from clinical samples.
A vicious cycle (hospitalization causes nosocomial in-
fections that result in longer hospitalization) is often triggered
within a patient, who is hospitalized with multimorbidity on
any severe health complaintdan infectious/noninfectious
disease that is often conducive to nosocomial superinfections
by any of the cohort of MDR bacteria (Enterobacter, Pseu-
domonas, Acinetobacter, Klebsiella, Escherichia, Staphylo-
coccus, etc.) as these are the most common pathogens in a
hospital environment. Depending upon age, immunological,
and other health status, the patient may have a longer stay inReducing sugars Saponins Tannins Flavonoids Steroids
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creating a situation for a longer hospital-stay. Such situations
are instantaneous, impromptu, and rife for enteropathogenic
bacteria, but especially serious for the other slow-killing,
parasitically compromising pathogens, such as Pseudomonas
or Staphylococcus.16,34 Somehow, some MDR bacteria are
acquired from the hospital environment by the patient.
In the USA, infection from GN bacteria caused two-third of
the total deaths occurring due to bacterial infections.35
Explicitly, diseases from blood stream, urinary tract, post-
operative and intra-abdominal infections are identified by
WHO as the four most common fatal bacterial infections.36
The latter category includes enteropathogenic diseases. The
concern is the lack of effectiveness of antibiotics; eventually,
societies across the world are affected by MDR strains of
pathogens that migrate from the spot of the emergence. Indeed
bacterial pathogens remain peripatetic depending upon the
degree of the acquired multiple drug resistance. Certain bac-
teria, Pseudomonas, Acinetobacter, and Klebsiella, have been
marked as pandrug resistant.23 Furthermore, infectious with
MDR E. coli of a variety of strains pathogenic to young and
old alike, in diseases of gastrointestinal and urinary tracts,
creates serious problems in public health, worldwide.37 Strains
of E. coli are among several determinative/causative agents of
infant and under-5 year olds mortality.38 Most enteropatho-
genic infections from Salmonella, Shigella, and Enterobacter
genera including Klebsiella pose worrying concern, due to the
lack of effective antibiotics.39 V. cholerae strains cause acute
problems due to sporadic outbreaks, which indicates that it is
slowly gaining multiple resistance to drugs; and such strains
continually precipitated fervent episodes, such as that seen in
Odisha, India.40 Another enteropathogen, Clostridium difficile
had been recorded as causing a violent outbreak in North
India.41 The outbreak of episodes due to enteropathogens has
been linked to household pets and food animals,42 and
contamination of coliforms in inland water reservoirs of
community and rivers.43 The bacterial pollution of inland
waters in developing countries, in which the marginalized
poverty-stricken population uses unpurified water inadver-
tently, is the main cause of infant and child mortality. Inci-
dentally, the death rate due to the drug-sensitive K.
pneumoniae strain was 12e18.9%, whereas rates due to MDR
K. pneumoniae strains were 33e43.8%.44 According to WHO,
in South East Asia region member states, death due to enteric
fever by MDR S. typhi was 10%, a value close to that due to
drug-sensitive S. typhi strain as 12.8%, recorded in the pre-
antibiotic era.45 In a study from Pakistan, it was recorded that
23 isolates of S. typhi had resistance to ciprofloxacin, chlor-
amphenicol, co-trimoxazole, and ampicillin in 2005, using
multiplex PCR that could demonstrate individual genes
responsible for resistance for individual antibiotics, catP
(chloramphenicol), tem (ampicillin) and gyrA (ciprofloxacin).
All these drugs were antityphoid, which were resistant to 23 S.
typhi strains.46 In a study from Nepal, it was seen that four
species of Shigella (S. dysenteriae, S. sonnei, S. flexneri, and S.
boydii) were resistant to three commonly used antibiotics:
ampicillin, co-trimoxazole, and nalidixic acid. Among thesefour species, S. sonnei and S. boydii were 100% resistant to co-
trimoxazole, and they were 100% sensitive to ciprofloxacin.47
V. cholerae O1 was isolated from New Delhi, which had high
levels of resistance to nalidixic acid, furazolidone, co-
trimoxazole, gentamicin, and tetracycline, but was sensitive
to chloramphenicol and cefotaxime. Thus, there was a limited
but critical resistant pattern in this destructive pathogen.48
Therefore, these enteropathogens need be controlled with an
iron hand in the Eastern developing world.
It is consensus that, for internal protection, antibiotic-
producing organisms carry antibiotic resistant genes in plas-
mids and chromosomes, which are often transposon medi-
ated.48,49 Therefore, such genes must have been taken up
horizontally by the susceptible group of bacteria, via bacterial
transformation and/or conjugation.50,51 Further, the expression
of antibiotic resistance in a pathogen is coexpressed with
virulence, demonstrated in E. coli with the mar-locus that
regulates the expression with 60 chromosomal genes, along
with the expression of multidrug resistance.52 The resultant
clinical consternation is the linkage between antibiotic resis-
tance and virulent gene regulation. It had been shown that
antibiotic susceptibility of bacteria is modulated by several
factors: growth phase, pH, carbon dioxide concentration,
temperature, salt concentration, and low iron content.53 In P.
aeruginosa, quinolone treatment at a subinhibitory level
induced the expression of certain bacterial genes, which a
priori should be expressive in quinolone-resistant strains of the
bacterium. Similarly, ciprofloxacin causes the Shiga-toxin
production by E. coli O157:H7 both in vitro and in an ani-
mal model.54 Thus, antibiotic stress induces the expression of
virulence at sublethal levels of the challenging antibiotic. In
such a situation, the use of combination therapy is suitable,
which should be ordinarily toxic to the host. The combination
therapy also proved dangerously host-toxic with treatments for
M. tuberculosis, discussed elsewhere.21 In addition, it has been
proven that quinolone-resistant S. aureus, when treated with a
subinhibitory concentration of any quinolone derivative
increased the expression of fibronectin-binding proteins
contributing to the emergence of virulent factor.55 It was
demonstrated that antibiotic treatment triggered the release of
bacterial products including an endotoxin and a lipopolysac-
charide, which reacted with the virulent character of patho-
genic bacteria.56,57 In addition, exposure to a low
concentration of antibiotics triggered the expression of sigma-
factors, which was linked to the virulence, demonstrated in M.
tuberculosis.58 Further, the induction of alterations in M.
tuberculosis genome by isoniazid, the drug of essential cate-
gory had been recorded,59 which probably promote the
emergence of drug resistance. Therefore, the effect of antibi-
otics in a mixture of drug-resistant and -sensitive pathogens is
a complex matter, as antibiotics/drugs control pathogens at
one level and induce the resistance at another level. In such a
situation, application of an antibiotic to a pathogen resistant to
the same class of antibiotic promotes epidemics, because of
the absence of a suitable/emulating control agent. It is
because, a situation of the presence of an antibiotic is limiting
to the majority (drug-sensitive strains) and remains an
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eventually, the later burgeons in the maze environment of the
mixture of antibiotics and bacteria.
Unless one is a clinical microbiologist, it would not occur to
mind that the acquired armamentarium of multiple drug resis-
tance in pathogenic bacteria has totally changed the infection
scenario of theworld to chaos. Additionally, several commensals
have been transformed to perilousMDRpathogens, by acquiring
drug resistant genes.22,29 Clinicians are becoming more
circumspect about empiric treatments of infections, as clinical
microbiologists have expressed astonishment on several bacte-
rial strains with artifices, such as chromosomal expression of
production of b-lactamases, aminoglycoside-inactivating en-
zymes, and antibiotic-inducible drug resistances, as MDR de-
terminants,55,60 eventually impeding treatment options for the
control.
A report, from Arunachal Pradesh, India, recorded ethno-
botanical literature on 25 plants against dysentery, with the
leading ones being Cassia fistula, Oroxylum indicum, and
Woodfordia fruticosa. Similarly, three plants for diarrhea, and
five plants for cholera including Curcuma longa have been
described.61 Further, from Tamil Nadu, India, 54 ethno-
medicinal plants used against diarrhea and dysentery,
excluding T. alata, were recorded.62 Another report from
Odisha and West Bengal, recorded the use of Holarrhena
antidysenterica and Terminalia arjuna, as ethnomedicinal
plants against diarrhea.63 ESBL-producing MDR strains of E.
coli and Shigella sp. were resistant to 16e23 antibiotics with
MIC values ranging from 16 mg/mL to 1024 mg/mL; extracts
of 12 plants were tested for these two MDR bacteria, and
crude-extracts of Acorus calamus, Hemidesmus indicus, H.
antidysenterica, and Plumbago zeylanica had been recorded as
having significant in vitro control capacities on these two
bacteria.25 Global data of multidrug resistance from individual
countries is lacking. Therefore, it was impossible to track and
take an account of outbreaks, and estimations of resistance
challenges posed by individual bacteria. Eventually, it is also
impossible to evaluate national and regional surveillance
conducted to contain the problem. Nevertheless, health
workers, stakeholders, and political systems of developed
countries are investigating the problem.64
Crude phytoextracts with too many natural compounds are
sometimes subjected to the process of slow degradation on
storage, for which those are often not actively considered. The
trilogy of “armada of chemotherapeutic drugs,” “suitable
dovetailed antibiotics,” and “bandwagon of phytodrugs of
finesse” could plausibly help the present crusade for MDR
enteropathogenic bacteria, if the principle of synergism in a
revised therapeutic module is adopted with adept; phytodrugs
could lend themselves for further manipulation in the drug
preparation. The antibacterial efficacy of methanolic crude
extracts reveals that leaves and bark of T. alata could serve as
CAM to control the MDR enteropathogenic bacteria. There
are many examples of uses of plants as medicines, even in
medical emergency.65 Enteropathogens are destructive human
parasites, as those trigger diarrhea and dysentery. The resultant
acute health effect rapidly cause life-threatening situations,unlike many other bacterial infections causing comorbidities
at other body sites due to balanced parasitism, such as due to
strains of Staphylococcus/Pseudomonas and a few more.
Enteropathogenic bacteria, when they become MDR, cause
failure in empiric therapy during the treatment, promoting a
life-threatening situation: the causative is not always V. chol-
erae. For the control of MDR enteropathogens, phytochemi-
cals would be appropriate because of their inherent chemical
diversity, which is unlikely to be breached by any MDR
bacterium, as seen here. If a suitable plant could be located,
for the control of a diverse range of MDR pathogens, it could
be employed for acute conditions. T. alata has a well-
established ethnobotanical history in the control of enteric
diseases. It would be prudent to use this plant during life-
threatening situations triggered by enteric diseases.
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